Positive airway pressure use tied to lower cardiovascular events
By
HealthDay News
Sep 17, 2024
Over several years, lower all-cause mortality and major adverse cardiovascular events can be seen.
Outdoor nighttime light exposure linked to prevalence of Alzheimer’s disease
By
Haymarket Media
Sep 06, 2024
Nighttime light exposure was more strongly linked to AD prevalence than any other disease factor among those younger than 65 years.
Adjunctive IV argatroban, eptifibatide do not cut disability after stroke
By
Haymarket Media
Sep 06, 2024
The findings were seen among patients with acute ischemic stroke who were treated with intravenous thrombolysis within three hours after symptom onset.
Disparities in post-acute stroke care depend on insurance status
Jul 17, 2024
Uninsured patients had the lowest odds of facility versus home discharge and home healthcare discharge versus home without home healthcare.
Reteplase superior to alteplase within 4.5 hours of ischemic stroke
Jun 20, 2024
Reteplase was more likely to result in excellent functional outcome than alteplase for ischemic stroke within 4.5 hours of symptom onset.
Endocrine Society, June 1-4
Jun 20, 2024
The conference highlighted recent advances in the diagnosis and management of obesity, endocrine disorders, diabetes, and growth hormone and thyroid diseases.
Prevalence of cardiovascular risk factors, diseases set to increase
Jun 06, 2024
The annual inflation-adjusted health care costs of cardiovascular risk factors is projected to triple between 2020 and 2050.
Fish oil beneficial for reducing risk for cardiovascular disease progression
May 22, 2024
However, supplements may be a risk factor for atrial fibrillation and stroke in the general population.
Prehospital reduction in BP does not improve stroke outcomes
May 20, 2024
The findings were seen in patients with suspected acute stroke with elevated systolic blood pressure.
ACP: Recommendations developed for newer type 2 diabetes medications
Apr 22, 2024
A strong recommendation was given for the addition of an SGLT-2 or GLP-1 agonist to metformin, and lifestyle modifications.